作者
Keith H Nuechterlein, Michael F Green, Robert S Kern, Lyle E Baade, Deanna M Barch, Jonathan D Cohen, Susan Essock, Wayne S Fenton, Frederick J Frese III, Ph D, James M Gold, Terry Goldberg, Robert K Heaton, Richard SE Keefe, Helena Kraemer, Raquelle Mesholam-Gately, Larry J Seidman, Ellen Stover, Daniel R Weinberger, Alexander S Young, Steven Zalcman, Stephen R Marder
发表日期
2008/2
期刊
American Journal of Psychiatry
卷号
165
期号
2
页码范围
203-213
出版商
American Psychiatric Association
简介
Objective
The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Method
The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered …引用总数
学术搜索中的文章
KH Nuechterlein, MF Green, RS Kern, LE Baade… - American Journal of Psychiatry, 2008